StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sangamo Therapeutics's operating income for the twelve months ending Mar 31, 2026 was -$123.56M. For fiscal 2025 it was -$121.24M. The highest annual figure on record is -$19.40M in fiscal 2009.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$121.24M–
FY2024Dec 31, 2024-$103.97M–
FY2023Dec 31, 2023-$274.01M–
FY2022Dec 31, 2022-$201.28M–
FY2021Dec 31, 2021-$183.34M–
FY2020Dec 31, 2020-$129.55M–
FY2019Dec 31, 2019-$105.18M–
FY2018Dec 31, 2018-$77.15M–
FY2017Dec 31, 2017-$56.36M–
FY2016Dec 31, 2016-$72.56M–
FY2015Dec 31, 2015-$46.86M–
FY2014Dec 31, 2014-$26.78M–
FY2013Dec 31, 2013-$26.71M–
FY2012Dec 31, 2012-$22.20M–
FY2011Dec 31, 2011-$35.82M–
FY2010Dec 31, 2010-$24.94M–
FY2009Dec 31, 2009-$19.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$31.95M–
Q4 FY2025Dec 31, 2025-$38.20M–
Q3 FY2025Sep 30, 2025-$35.55M-434.4%
Q2 FY2025Jun 30, 2025-$17.86M–
Q1 FY2025Mar 31, 2025-$29.63M–
Q4 FY2024Dec 31, 2024-$25.99M–
Q3 FY2024Sep 30, 2024$10.63M–
Q2 FY2024Jun 30, 2024-$37.08M–
Q1 FY2024Mar 31, 2024-$51.53M-385.7%
Q4 FY2023Dec 31, 2023-$62.06M–
Q3 FY2023Sep 30, 2023-$106.41M–
Q2 FY2023Jun 30, 2023-$123.57M–
Q1 FY2023Mar 31, 2023$18.03M–
Q4 FY2022Dec 31, 2022-$55.39M–
Q3 FY2022Sep 30, 2022-$54.89M–
Q2 FY2022Jun 30, 2022-$45.73M–
Q1 FY2022Mar 31, 2022-$45.26M–
Q4 FY2021Dec 31, 2021-$39.90M–
Q3 FY2021Sep 30, 2021-$48.44M–
Q2 FY2021Jun 30, 2021-$48.70M–
Q1 FY2021Mar 31, 2021-$46.30M–
Q4 FY2020Dec 31, 2020-$43.43M-3056.6%
Q3 FY2020Sep 30, 2020-$3.70M–
Q2 FY2020Jun 30, 2020-$37.90M–
Q1 FY2020Mar 31, 2020-$44.52M–
Q4 FY2019Dec 31, 2019$1.47M–
Q3 FY2019Sep 30, 2019-$29.25M–
Q2 FY2019Jun 30, 2019-$33.50M–
Q1 FY2019Mar 31, 2019-$43.90M–
Q4 FY2018Dec 31, 2018-$20.77M–
Q3 FY2018Sep 30, 2018-$16.24M–
Q2 FY2018Jun 30, 2018-$19.14M–
Q1 FY2018Mar 31, 2018-$21.00M–
Q4 FY2017Dec 31, 2017-$13.77M–
Q3 FY2017Sep 30, 2017-$13.04M–
Q2 FY2017Jun 30, 2017-$12.77M–
Q1 FY2017Mar 31, 2017-$16.79M–
Q4 FY2016Dec 31, 2016-$9.83M–
Q3 FY2016Sep 30, 2016-$19.21M–
Q2 FY2016Jun 30, 2016-$26.84M–

More Sangamo Therapeutics figures

See a number that looks wrong?